ANDA 212902, held by Pharmazone. Hydroxychloroquine Sulfate.
As of Nov 15, 2026, ANDA 212902 (Hydroxychloroquine Sulfate), held by Pharmazone, was first approved by FDA on May 14, 2020, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 14, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydroxychloroquine Sulfate200MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Oct 5, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 5, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 5, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 14, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters